{"id":48243,"date":"2022-09-12T14:01:59","date_gmt":"2022-09-12T12:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/"},"modified":"2022-09-12T14:01:59","modified_gmt":"2022-09-12T12:01:59","slug":"dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/","title":{"rendered":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Dr. Schott will oversee the advancement of Nutcracker Therapeutics\u2019 oncology pipeline, helping to expand the company\u2019s novel RNA therapeutics platform<\/i>\n<\/li>\n<li>\n<i>The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics\u2019 executive team<\/i>\n<\/li>\n<\/ul>\n<p>EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nutcrackerx.com%2F&amp;esheet=52879158&amp;newsitemid=20220912005082&amp;lan=en-US&amp;anchor=Nutcracker+Therapeutics%2C+Inc.&amp;index=1&amp;md5=615e5651fed21cd8b51a0ed60b88c29f\" rel=\"nofollow noopener\" shape=\"rect\">Nutcracker Therapeutics, Inc.<\/a>, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer. Dr. Schott joins Nutcracker Therapeutics ahead of planned major clinical milestones for its lead program, NTX-0250, and will guide the clinical advancement of the company\u2019s oncology pipeline.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/5\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\"><\/a><\/p>\n<p>\n\u201cRob\u2019s extensive background, which includes driving successful clinical development programs within the pharmaceutical and biotechnology industries, gives us full confidence in his ability to oversee the continuous evolution of our pipeline,\u201d said Igor Khandros, Ph.D., cofounder and Chief Executive Officer of Nutcracker Therapeutics. \u201cThe biological versatility of RNA equips Nutcracker Therapeutics with the tools to reimagine the treatment landscape of oncology, and beyond,\u201d explained Khandros. \u201cDr. Schott\u2019s robust track record adds a new dimension of invaluable industry know-how to a team of talented individuals working to bring transformative RNA therapies to patients.\u201d\n<\/p>\n<p>\nDr. Schott comes to Nutcracker Therapeutics from Sangamo Therapeutics, where he held the position of Senior Vice President and Head of Development, spearheading clinical strategy across numerous programs. Prior to Sangamo, Dr. Schott served as Chief Medical Officer at Chorus, an operationally independent subsidiary of Eli Lilly and Company, focused on expanding the latter\u2019s pipeline via early-phase candidate selection and discovery. While at Chorus, Dr. Schott led the implementation of innovative processes designed to achieve clinical proof-of-concept more efficiently for early-stage drug candidates.\n<\/p>\n<p>\nDr. Schott\u2019s earlier career as a practicing cardiologist led to his role at Sacramento\u2019s Sutter Medical Center as Cardiovascular Department Chair and Vice President of Medical Affairs. He attended the University of Michigan, where he earned his undergraduate and medical degrees. He then worked as a postdoctoral fellow at the Harvard Medical School before training in cardiovascular medicine at Massachusetts General Hospital.\n<\/p>\n<p>\n\u201cI see RNA as a drug modality with enormous potential, so I immediately connected with Nutcracker Therapeutics\u2019 distinct methodology of RNA drug development,\u201d commented Dr. Schott. \u201cThe unique ability of the company\u2019s technology platform to rapidly design and interrogate RNA molecules will be key to realizing the therapeutic potential of this drug class within oncology and beyond. I look to utilize my clinical expertise to advance Nutcracker Therapeutics\u2019 pipeline and contribute to a culture built on dedication to improving patient lives.\u201d\n<\/p>\n<p>\nDr. Schott\u2019s appointment arrives on the heels of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nutcrackerx.com%2Fabout%2Fnews%2Fnews-detail%2F%3Fnews_id%3D1831&amp;esheet=52879158&amp;newsitemid=20220912005082&amp;lan=en-US&amp;anchor=several+other+recent+additions&amp;index=2&amp;md5=42cf11323ca8a94dc4ab6b5653a2bfc3\" rel=\"nofollow noopener\" shape=\"rect\">several other recent additions<\/a>, bolstering a tested leadership core, including John Stubenrauch, Ph.D., as Chief Operating Officer, who had served as Vice President of Biologics Commercial Operations at Gilead Sciences. Drs. Schott and Stubenrauch join the company after the unveiling of Nutcracker Therapeutics\u2019 oncology pipeline in June, comprising three mRNA candidates targeting HPV-driven tumors, T-cell lymphoma, and genitourinary tumors.\n<\/p>\n<p>\n<b>About Nutcracker Therapeutics, Inc.<\/b>\n<\/p>\n<p>\nNutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics\u2019 technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.\n<\/p>\n<p>\nFor more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nutcrackerx.com&amp;esheet=52879158&amp;newsitemid=20220912005082&amp;lan=en-US&amp;anchor=www.nutcrackerx.com&amp;index=3&amp;md5=60f438e833edc920daa7f62cded712f3\" rel=\"nofollow noopener\" shape=\"rect\">www.nutcrackerx.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAzeem Zeekrya<br \/>\n<br \/>HDMZ<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#x74;&#x6f;&#x3a;&#x61;ze&#101;&#109;&#x2e;&#x7a;&#x65;&#x65;kr&#121;&#97;&#64;&#x68;&#x64;&#x6d;&#x7a;&#46;c&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">a&#122;&#101;&#x65;&#x6d;&#46;z&#101;&#101;&#x6b;&#x72;ya&#64;&#104;&#x64;&#x6d;z&#46;&#99;&#x6f;&#x6d;<\/a><br \/>(312) 506-5244\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Schott will oversee the advancement of Nutcracker Therapeutics\u2019 oncology pipeline, helping to expand the company\u2019s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics\u2019 executive team EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48243","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Dr. Schott will oversee the advancement of Nutcracker Therapeutics\u2019 oncology pipeline, helping to expand the company\u2019s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics\u2019 executive team EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T12:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer\",\"datePublished\":\"2022-09-12T12:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/\"},\"wordCount\":619,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005082\\\/en\\\/1566426\\\/21\\\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/\",\"name\":\"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005082\\\/en\\\/1566426\\\/21\\\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\",\"datePublished\":\"2022-09-12T12:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005082\\\/en\\\/1566426\\\/21\\\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005082\\\/en\\\/1566426\\\/21\\\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend","og_description":"Dr. Schott will oversee the advancement of Nutcracker Therapeutics\u2019 oncology pipeline, helping to expand the company\u2019s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics\u2019 executive team EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-12T12:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer","datePublished":"2022-09-12T12:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/"},"wordCount":619,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/","name":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg","datePublished":"2022-09-12T12:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220912005082\/en\/1566426\/21\/ab40ddc8-88c3-4666-a6f4-2581dc0f4146-1592946689870_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dr-rob-schott-joins-nutcracker-therapeutics-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48243"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48243\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}